A clinical study for cardioprotective effect of empagliflozin in T2DM patients with heart failure and exploring associated factors - Effect of empagliflozin for HFpEF with Type2 DM (EMPOWERMENT)

Kyushu University Hospital0 个研究点目标入组 50 人开始时间: 2017年6月2日最近更新: 2024年4月1日

适应症

试验速览

暂无简介。

•1)Other than T2DM such as T1DM and secondary DM. 2)Patients with severe infection, perioperative patients, patients with severe trauma. 3)Patients receiving SGLT2 inhibitor and/or incretin-related drugs within 2 months before ingestion of study drug. 4)Patients with idiopathic cardiomyopathy, Fabry disease, Amyloidosis cardiomyopathy. 5)Patients with renal insufficiency (eGFR< 45 ml/min/1.73m2). 6)Patients with severe respiratory disease, severe musculoskeletal conditions and unable to exercise challenge test for any other diseases, and severe anemia. 7)Any uncontrolled endocrine disorder except type 2 diabetes. 8)Acute coronary syndrome, stroke, or transient ischemic attack within 3 months of IC. 9)Patient who is scheduled to undergo surgery within 3 months before IC or plan to operate within 3 months after IC. 10)Patients who have a heart pacemaker, who have an aneurysm clip in their brain more than 20 years ago, or have a body implantation device (Implanted cardioverter-defibrillator , Cochlear, otologic, or other ear implant, or Neurostimulation system). 11)Patients with severe claustrophobia. 12)Patients who are pregnant or breast-feeding. 13)Patients lower than BMI 20. 14)Patients in hyperglycemic crisis or accompanied with marked symptom of hyperglycemia and /or DKA. 15)Patients considered inappropriate to participate in the study by the principal and/or sub- investigators.

发起方